Table 1.
Baseline clinical characteristics of subjects who have an sRAGE measurement by cohort
| COPDGene (n = 1443) | ECLIPSE (n = 2349) | SCCOR (n = 399) | SPIROMICS (n = 1623) | p-value | |
|---|---|---|---|---|---|
| Age (mean ± SD) | 61 ± 9 | 62 ± 8 | 65 ± 6 | 64 ± 9 | < 0.001 |
| Sex (male) (%) | 49% | 62% | 53% | 54% | < 0.001 |
| Race (%) | |||||
| Non-Hispanic White | 86% | 93.5% | 95% | 75% | < 0.001 |
| Non-Hispanic African American | 14% | 1.5% | 4% | 16% | |
| Other | 0% | 5% | 1% | 9% | |
| BMI (kg/m2) (mean ± SD) | 29 ± 6 | 27 ± 5 | 28 ± 4 | 28 ± 5 | < 0.001 |
| Never Smoker (%) | 2% | 9% | 0% | 8% | < 0.001 |
| Current Smoker (%) | 39% | 35% | 42% | 34% | |
| Pack-years median (5th and 95th percentile) | 38.4 (11.3; 90.0) | 39 (0; 95) | 46.0 (19.0; 118.0) | 42.0 (0; 96.0) | < 0.001 |
| COPD (%) | 41% | 78% | 48% | 62% | < 0.001 |
| PRISm (%) | 10% | 0.2% | 5% | 2% | < 0.001 |
| FEV1 (% predicted) (mean ± SD) | 81 ± 25 | 62 ± 30 | 83 ± 20 | 76 ± 26 | < 0.001 |
| FEV1 (L) (mean ± SD) | 2.36 ± 0.91 | 1.79 ± 1.00 | 2.39 ± 0.76 | 2.15 ± 0.91 | < 0.001 |
| FVC (L) (mean ± SD) | 3.44 ± 1.00 | 3.30 ± 1.03 | 3.54 ± 0.89 | 3.44 ± 1.02 | 0.006 |
| Emphysema (% LAA < − 950 HU) median (5th and 95th percentile) | 1.40 (0.08; 26.19) | 11.48 (0.49; 39.18) | 0.80 (0.10; 17.40) | 3.07 (0.29; 29.54) | < 0.001 |
| PD15adj (g/L) (mean ± SD) | 89 ± 24 | 61 ± 26 | 87 ± 21 | 83 ± 26 | < 0.001 |
| History of diabetes (%) | 11% | 9% | 8% | 13% | < 0.001 |
| History of heart attack (%) | 6% | 8% | 5% | 6% | 0.009 |
| History of coronary artery disease (%) | 7% | NC | 6% | 9% | 0.12 |
| History of stroke (%) | 2% | 3% | 3% | 4% | 0.11 |
| Follow-up (years) median (5th and 95th percentile) | 5.14 (0; 10.1) | 3.0 (1.5; 3.0) | 6.0 (2.0; 6.0) | 3.1 (0; 7.5) | < 0.001 |
| Percentage of visits with a spirometry per participant | |||||
| 0 | 0.1% | 0.1% | |||
| 1 | 39% | 0.04% | 12% | ||
| 2 | 44% | 0.04% | 39% | 12% | |
| 3 | 16% | 1% | 61% | 18% | |
| 4 | 4% | 34% | |||
| 5 | 4% | 24% | |||
| 6 | 5% | ||||
| 7 | 10% | ||||
| 8 | 76% | ||||
| Number of visits with CT scan per participant | |||||
| 0 | 1% | 7% | 0.1% | ||
| 1 | 41% | 11% | 13% | ||
| 2 | 58% | 21% | 39% | 50% | |
| 3 | 61% | 61% | 36% | ||
To evaluate differences between cohorts, analysis of variance (ANOVA) was used for normally distributed continuous variables and Kruskal–Wallis test for non-normaly distributed variables; and a Chi square/Fisher’s exact test for categorical
COPD chronic obstructive pulmonary disease, PRISm Preserved Ratio Impaired Spirometry, FEV1 forced expiratory volume in one second, FVC forced vital capacity, PD15adj HU of the 15th Percentile adjusted for total lung capacity, NC not collected